We didn't build a bigger model. We built a better description. iScore stands out through its abstraction of the complex 3D chemical space so efficiently that accurate binding poses are predicted in real time, by a single tested model that generalises across targets.
"ANYO Labs novel in silico AI-driven screening program allows for rapid and cost-efficient exploration of an extremely large portion of chemical space, which cannot be matched by any other in silico drug discovery tool."
- Prof. Johan Lennerstrand
Rapidly uncovering accurate starting points for drug engineering.
Applying our tools to enhance compounds using
Applying our tools and experience to optimize your compound through multiparameter optimization.
How we work
We're actively seeking innovative partners to collaborate on ground-breaking discovery projects. Utilising our efficient methods, we deliver results in only days to weeks, with risk adjusted terms.
Work with us to take new chemical entities to validation faster with a defined project scope and clear objectives. We currently partner with early stage projects in both small molecules and peptides for : 1. Large scale virtual screenings 2. Generative AI modelling & screening 3. ADMET predictions 4. Lead optimization projects
Work with our computational chemists closely to have control and understanding of the project execution.
Work under a limited project scope to accelerate development. We agree to terms set forth by you.
Experienced in working with early to late stage pharmaceutical companies, we offer pure fee-for-service agreements as well as milestone and success based terms, all while giving full IP and data rights back to you.
Collaborate with Anyo Labs to jointly develop novel treatments, sharing the risk and reward along the way. Ideal for early stage long-term commitments for academics and biotechnology companies alike.
Commitment to enhance discovery from target to preclinical candidate. You define the need, we deliver you prioritised in silico results under 1 streamlined agreement.
Used to share the risks associated with drug development.
Designed to keep a clear IP ownership structure to allow future out-licensing.
| Target/Pathway | Target | Partner | Target ID | Hit identification | Hit to lead | Lead optimization | Pre-clinical studies | Clinical trial approval |
|---|---|---|---|---|---|---|---|---|
| Oncology | Undisclosed Kinase | Yes | Hit identification | |||||
| Inflammatory | Hydrolase | No | Hit to lead | |||||
| Oncology | Undisclosed | Yes | Target ID | |||||
| Oncology | Undisclosed | Yes | Lead optimization | |||||
| Inflammation | Novel NLRP3 site | No | Target ID | |||||
